Drugs / GLPG0259
Trials 5 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 14 trials | ||||||
| Phase 1 | NCT01322451 | Nov → Dec 2010 | — | Lakefront Biotherapeutics NV | Completed | No outcome recorded |
| Phase 1 | NCT01024517 | Nov → Dec 2009 | — | Lakefront Biotherapeutics NV | Completed | No outcome recorded |
| Phase 1 | NCT00989703 | Sep → Nov 2009 | — | Lakefront Biotherapeutics NV | Completed | No outcome recorded |
| Phase 1 | NCT00905138 | Mar → Jun 2009 | — | Lakefront Biotherapeutics NV | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT01211249 | Oct 2010 → Apr 2011 | rheumatoid arthritis | Lakefront Biotherapeutics NV | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GLPG0259 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00905138 ↗ |
| Action | Inhibit | “Oral administration of GLPG0259, an inhibitor of MAPKAPK5, a new target for the ” PMID 23161899 ↗ Nov 2012 |
| Modality | Small molecule | — CHEMBL5095028 ↗ |
| Route | Oral | “multiple oral doses” NCT00905138 ↗ |
| Target | MAPKAPK5 | “Oral administration of GLPG0259, an inhibitor of MAPKAPK5, a new target for the ” PMID 23161899 ↗ Nov 2012 |